Catalyst Wire Dossier Catalyst Wire Dossier

Molnupiravir

molnupiravir · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

14 regulatory and trial events tracked for Molnupiravir, covering 2021-10-25 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) [Phase 3]

See pricing